Jump to main content
Jump to site search

Issue 23, 2013
Previous Article Next Article

Alzheimer's disease: which type of amyloid-preventing drug agents to employ?

Author affiliations

Abstract

The current paradigm in the amyloid hypothesis brands small β-amyloid (Aβ) oligomers as the toxic species in Alzheimer's disease (AD). These oligomers are fibril-like; contain β-sheet structure, and present exposed hydrophobic surface. Oligomers with this motif are capable of penetrating the cell membrane, gathering to form toxic ion channels. Current agents suppressing precursor Aβ cleavage have only met partial success; and to date, those targeting the peptides and their assemblies in the aqueous environment of the extracellular space largely fail in clinical trials. One possible reason is failure to reach membrane-embedded targets of disease-‘infected’ cells. Here we provide an overview, point to the need to account for the lipid environment when aiming to prevent the formation of toxic channels, and propose a combination therapy to target the species spectrum.

Graphical abstract: Alzheimer's disease: which type of amyloid-preventing drug agents to employ?

Back to tab navigation

Publication details

The article was received on 02 Jan 2013, accepted on 20 Feb 2013 and first published on 21 Feb 2013


Article type: Perspective
DOI: 10.1039/C3CP00017F
Citation: Phys. Chem. Chem. Phys., 2013,15, 8868-8877
  •   Request permissions

    Alzheimer's disease: which type of amyloid-preventing drug agents to employ?

    H. Jang, L. Connelly, F. T. Arce, S. Ramachandran, R. Lal, B. L. Kagan and R. Nussinov, Phys. Chem. Chem. Phys., 2013, 15, 8868
    DOI: 10.1039/C3CP00017F

Search articles by author

Spotlight

Advertisements